Home  |  Contact

UniProtKB/Swiss-Prot P35221: Variant p.Glu307Lys

Catenin alpha-1
Gene: CTNNA1
Variant information

Variant position:  307
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamate (E) to Lysine (K) at position 307 (E307K, p.Glu307Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (E) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In MDPT2; no effect on VCL-binding.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  307
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  906
The length of the canonical sequence.

Location on the sequence:   KQIIVDPLSFSEERFRPSLE  E RLESIISGAALMADSSCTRD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KQIIVDPLSFSEERFRPSLEERLESIISGAALMADSSCTRD

Mouse                         KQIIVDPLSFSEERFRPSLEERLESIISGAALMADSSCTRD

Bovine                        KQIIVDPLSFSEERFRPSLEERLESIISGAALMADSSCTRD

Rabbit                        KQIIVDPLSFSEERFRPSLEERLESIISGAALMADSSCTRD

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 906 Catenin alpha-1
Modified residue 295 – 295 Phosphoserine
Modified residue 297 – 297 Phosphoserine
Alternative sequence 1 – 370 Missing. In isoform 3.
Helix 305 – 316


Literature citations

Mutations in CTNNA1 cause butterfly-shaped pigment dystrophy and perturbed retinal pigment epithelium integrity.
Saksens N.T.; Krebs M.P.; Schoenmaker-Koller F.E.; Hicks W.; Yu M.; Shi L.; Rowe L.; Collin G.B.; Charette J.R.; Letteboer S.J.; Neveling K.; van Moorsel T.W.; Abu-Ltaif S.; De Baere E.; Walraedt S.; Banfi S.; Simonelli F.; Cremers F.P.; Boon C.J.; Roepman R.; Leroy B.P.; Peachey N.S.; Hoyng C.B.; Nishina P.M.; den Hollander A.I.;
Nat. Genet. 48:144-151(2016)
Cited for: INVOLVEMENT IN MDPT2; VARIANTS MDPT2 CYS-54; LYS-307; SER-318 AND MET-431; INTERACTION WITH VCL;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.